Loop diuretics inhibit the Na-K-2Cl cotransporter (NKCC2) on the luminal surface of the thick ascending limb of the loop of Henle, the segment responsible for reabsorbing approximately 25–30% of filtered sodium.¹ Blocking NKCC2 produces a large natriuresis and diuresis, reduces plasma volume, and, of particular relevance in acutely decompensated HF, rapidly reduces ventricular filling pressures (preload) within 30–60 minutes of IV administration, preceding any measurable change in urine output. The early hemodynamic benefit (reduced dyspnea within minutes of IV furosemide) is partly attributable to venodilation mediated by prostaglandin and nitric oxide release rather than diuresis alone.¹ Downstream consequences of NKCC2 blockade include obligatory urinary losses of potassium (through increased delivery of sodium to the cortical collecting duct, where Na-K exchange occurs), magnesium, and calcium: electrolyte disturbances that require active management in the HF patient.

Furosemide: The most widely used loop diuretic globally. Oral bioavailability is variable (10–100%, average ~50%) and decreases further in decompensated HF due to gut wall edema impairing absorption.¹ This is one of the primary reasons for transitioning to IV furosemide during acute decompensation: IV administration bypasses gut absorption variability and delivers predictable drug concentrations to the thick ascending limb. The onset of diuresis after IV furosemide is 5–30 minutes; duration 2 hours (IV) to 4–6 hours (oral). Furosemide is extensively protein-bound (>95%) and is secreted into the tubular lumen via organic acid transporters in the proximal tubule: secretion that competes with endogenous organic acids accumulating in renal failure, contributing to reduced tubular drug delivery in CKD.¹ Oral-to-IV dose conversion: In decompensated HF, the standard approach is to convert the total oral furosemide daily dose to IV in mg equivalents (i.e., if the patient takes oral furosemide 80 mg BID at home, start with IV furosemide 80 mg BID). Some evidence (DOSE trial) supports that a higher starting IV dose (2.5× the oral dose) produces faster decongestion without significantly worsening renal function.¹

Torsemide: Oral bioavailability approximately 80–90% (much higher and more consistent than furosemide), making it pharmacokinetically superior for outpatient use in chronic HF.¹ Torsemide is also longer-acting (duration 6–8 hours vs. furosemide 4–6 hours), potentially producing more complete 24-hour diuresis. The TRANSFORM-HF trial (2023) compared torsemide to furosemide as maintenance therapy in patients hospitalized with HF. While the trial did not demonstrate a significant difference in all-cause mortality (HR 1.02; 95% CI 0.89–1.18) or the composite of mortality and hospitalization (HR 0.92; 95% CI 0.83–1.02), torsemide was associated with fewer diuretic-related side effects and better quality-of-life metrics in some analyses.³ Many clinicians favor torsemide over furosemide for outpatient maintenance therapy on pharmacokinetic grounds. Starting dose: 10–20 mg daily; typical maintenance range 10–200 mg daily. Bumetanide: High oral bioavailability (~80%), short duration of action (4–6 hours). Potency ratio approximately 40:1 vs. furosemide (40 mg furosemide ≈ 1 mg bumetanide ≈ 20 mg torsemide). Useful in patients with allergy to furosemide's sulfonamide side chain (though cross-reactivity is variable). Available in IV and oral formulations.¹

In acute decompensated HF requiring hospitalization: initiate IV loop diuretic immediately upon diagnosis. Target: urine output 3–5 mL/kg/hour, with net fluid removal of 1–2 liters per day on average, guided by clinical reassessment. The DOSE trial (2011) compared continuous IV infusion vs. bolus dosing and high vs. low dose of furosemide.¹ Key findings: (1) No significant difference in outcomes between continuous infusion and intermittent bolus dosing; (2) High-dose diuresis (2.5× oral dose) produced greater decongestion and symptomatic improvement vs. low-dose (1× oral dose) at 72 hours, with a modest but non-significant increase in creatinine that did not translate into worse outcomes. Based on DOSE and subsequent data, current practice favors: - IV bolus dosing at 2.5× the home oral dose BID or TID - Reassess response by 6 hours; if urine output is inadequate (<100–150 mL/hour), increase the dose by 50% or add a second diuretic mechanism (thiazide or acetazolamide) - Target weight loss and reassess symptoms, jugular venous pressure (JVP), and oxygen requirements daily - Transition to oral furosemide when the patient is euvolemic and clinically stable, using oral furosemide at a dose equivalent to the effective IV dose¹

In chronic outpatient HF management, the goal is maintenance of euvolemia with the minimum diuretic dose sufficient to prevent fluid accumulation. Patient self-management is critical: educate patients to weigh themselves daily, report weight gain >2 kg over 2–3 days, and adjust furosemide dose accordingly using a "flexible dosing" protocol. Flexible dosing (allowing the patient to increase furosemide by one dose for 2 days with any 2 kg weight gain) has been shown to reduce HF hospitalizations.¹

Diuretic resistance is defined as persistent fluid overload despite adequate doses of loop diuretics. It is a common and clinically important problem in advanced HF, and understanding its mechanisms guides rational management: Mechanisms of diuretic resistance in HF: (1) Reduced oral bioavailability: Gut wall edema in decompensated HF impairs furosemide absorption. Solution: switch to IV administration or switch to torsemide (higher oral bioavailability). (2) Reduced renal perfusion: Low cardiac output and/or excessive prior diuresis reduce renal blood flow, decreasing delivery of loop diuretic to the proximal tubule secretion sites. Solution: optimize cardiac output (review adequacy of GDMT, consider hemodynamic assessment); cautious fluid challenge may occasionally paradoxically improve diuretic response in pre-renal states. (3) Distal nephron hypertrophy (braking phenomenon): Chronic loop diuretic use induces compensatory hypertrophy of distal tubule cells with upregulation of the Na-Cl cotransporter (NCC), partially reclaiming the sodium that loop diuretics delivered distally. Solution: add a thiazide or thiazide-like diuretic to block the NCC, synergistically enhancing natriuresis: "sequential nephron blockade." (4) Neurohormonal activation: Aldosterone-driven sodium retention in the collecting duct partially offsets diuresis. Solution: ensure MRA is included in the regimen; aldosterone antagonism (spironolactone, eplerenone) blocks collecting duct sodium reabsorption.

(5) NSAID use: NSAIDs inhibit prostaglandin synthesis, reducing renal blood flow and blunting the prostaglandin-mediated vasodilatory component of loop diuretic action. Solution: discontinue NSAIDs. (6) Hypoalbuminemia: Loop diuretics are protein-bound; hypoalbuminemia reduces drug delivery to the tubular lumen. This mechanism is more relevant in nephrotic syndrome than in isolated HF, but can compound resistance in patients with both.

Sequential nephron blockade: Adding a thiazide diuretic (hydrochlorothiazide 25–50 mg daily or metolazone 2.5–5 mg daily) to a loop diuretic blocks distal tubule NCC and dramatically amplifies natriuresis.¹ Metolazone has the advantage of effectiveness even at low eGFR (unlike hydrochlorothiazide, which loses efficacy at eGFR <30 mL/min/1.73m²). This combination requires very close monitoring: risk of profound electrolyte disturbances (hypokalemia, hypomagnesemia, hyponatremia) and excessive volume depletion. Metolazone is typically reserved for in-hospital use or closely monitored outpatient escalation; continuous use is rarely appropriate. Acetazolamide: The ADVOR trial (2022) randomized 519 patients with acute decompensated HF to IV acetazolamide (carbonic anhydrase inhibitor, blocks proximal tubule sodium bicarbonate reabsorption) vs. placebo on background loop diuretic.⁴ Acetazolamide significantly increased the rate of successful decongestion (defined as absence of signs of congestion at 3 days) vs. placebo (42.2% vs. 30.5%; RR 1.46; p<0.001). This trial established a role for acetazolamide in combination with loop diuretics during acute decompensation to enhance diuretic response, though it is not yet widely incorporated into routine practice.

The combination of a loop diuretic (potassium-wasting) and an MRA (potassium-sparing) in the same patient requires active management of serum potassium. Loop diuretics reduce potassium by increasing distal tubular sodium delivery, whereas MRAs reduce the aldosterone-driven potassium wasting at the collecting duct. In practice, when both are used together: (1) Hypokalemia from loop diuretic over-diuresis becomes a risk when MRA doses are insufficient or renal function worsens; (2) Hyperkalemia from MRA becomes a risk when the loop diuretic is reduced, renal function deteriorates, or when renin-angiotensin-aldosterone system (RAAS) blockade is intensified. The net effect on potassium depends on the balance of these forces. Target potassium in HF: 4.0–5.0 mEq/L. Hypokalemia (K⁺ <4.0 mEq/L) increases the risk of ventricular arrhythmias and should be actively corrected through diuretic dose reduction, dietary potassium, or oral supplementation.¹

In HFpEF (LVEF ≥50%), diuretics remain the primary tool for symptom management. Unlike HFrEF, the evidence for survival-modifying pharmacotherapy in HFpEF is limited (until recently with sodium-glucose cotransporter 2 (SGLT2) inhibitors), and diuretics are the mainstay of decongestion. MRAs in HFpEF have been studied in the TOPCAT trial (spironolactone vs. placebo in HFpEF): while the overall trial showed only a non-significant trend toward mortality reduction, subgroup analyses by geography suggested benefit in patients from the Americas.⁸ Current guidelines give MRAs an IIb recommendation in HFpEF in the presence of persistent symptoms.²

Worsening renal function (WRF) during aggressive diuresis, defined as a rise in creatinine of ≥0.3 mg/dL, occurs in 20–40% of hospitalizations for acute decompensated HF. Post-hoc analyses have shown that WRF during appropriate diuresis in HF does not necessarily portend poor outcomes; persistent congestion after discharge is actually a stronger predictor of 30-day readmission than in-hospital WRF during adequate diuresis.¹ The concept of "acceptable WRF" (a modest creatinine rise during effective decongestion in the absence of signs of true renal ischemia) has shifted clinical practice away from premature diuretic discontinuation based solely on rising creatinine. If WRF occurs, the clinical question is: (1) Is the patient still congested? If yes, continue diuresis cautiously. (2) Are there signs of true hypoperfusion (cool extremities, falling BP, oliguria)? If yes, pause diuresis and reassess hemodynamics. (3) Is the patient over-diuresed (low JVP, orthostatic hypotension, dry mucous membranes)? If yes, reduce or hold diuresis.